Subconjunctival corticosteroid injection for the treatment of non-necrotising anterior scleritis.

Scleritis commonly is a recurrent disease that requires long term immunosuppressive treatment that can be associated with significant adverse effects. Although topical and periorbital steroids are accepted therapeutic options for treatment of scleritis, subconjunctival administration of depot corticosteroids has been considered unsafe owing to the risk of scleral thinning and perforation. Recently, this has been challenged by reports describing the safe and effective use of subconjunctival depot steroid injections in patients with non-necrotising scleritis. Based on these reports we reviewed our experience using subconjunctival corticosteroid injections (SCI) in the management of non-infectious, non-necrotising anterior scleritis.